NeuroVive Pharmaceutical AB ROCE
What is the ROCE of NeuroVive Pharmaceutical AB?
The ROCE of NeuroVive Pharmaceutical AB is -54.74%
What is the definition of ROCE?
Return on capital employed (ROCE) is a financial ratio that measures a company’s profitability and the efficiency with which its capital is used.
= EBIT / (assets - current liabilities)
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE of companies in the Health Care sector on OTC compared to NeuroVive Pharmaceutical AB
What does NeuroVive Pharmaceutical AB do?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Companies with roce similar to NeuroVive Pharmaceutical AB
- Chinook Therapeutics has ROCE of -55.30%
- FSD Pharma Inc has ROCE of -55.28%
- Liberty Gold has ROCE of -55.23%
- Aaj Capital 3 Corp has ROCE of -54.85%
- Jones Soda Co has ROCE of -54.84%
- Windtree Therapeutics has ROCE of -54.81%
- NeuroVive Pharmaceutical AB has ROCE of -54.74%
- Northstar Gold has ROCE of -54.72%
- Emergent Biosolutions Inc has ROCE of -54.69%
- Top 10 Split Trust has ROCE of -54.59%
- Synaptogenix Inc has ROCE of -54.32%
- Psychemedics has ROCE of -54.26%
- BiomX Inc has ROCE of -54.24%